NEWARK, Calif.--(BUSINESS WIRE)--ATUM, a leading US-based provider of integrated biologics solutions, proudly announces the launch of the CHO-K1-derived discoCHO™ cell line for transient protein production. ATUM’s discoCHO enables robust transient therapeutic protein expression displaying critical quality attributes similar to those of the stable CHO-K1 manufacturing cell line miCHO-GS.
CHO-K1 cells are the dominant cell line used in manufacturing protein-based biologics. However, CHO-K1-derived cells have historically generated low protein yields in the transient production processes used in early discovery. Therefore, HEK cell lines are typically employed during this discovery stage to generate the required protein quantities for evaluation. However, these HEK platforms express antibodies with Critical Quality Attributes (CQA) do not match the final CHO-K1-derived manufacturing cell line. This results in poor predictability of protein characteristics from discovery to development.
With the launch of ATUM’s CHO-K1-derived discoCHO for robust transient productivity in combination with ATUM’s existing miCHO-GS cell line (derived from the same CHO-K1 host) for stable biologics production, ATUM’s platform now provides a fast, productive, and predictable ecosystem bridging early discovery to commercialization.
Jeremy Minshull, Ph.D., co-founder and chief executive officer at ATUM, remarked, "The introduction of discoCHO for antibody production enhances our industry-leading ecosystem, providing our customers with an exceptionally efficient and consistent process to bring drugs to market faster while minimizing risks."
The launch of discoCHO enhances ATUM’s integrated pipeline to support our customers step-by-step, from electronic sequence and design through early-stage protein production and detailed analytics, culminating with Leap-In Transposase® derived stable cell line development and GMP master cell banking. ATUM’s state-of-the-art facility provides a comprehensive solution under one roof where our customers’ confidential sequences never leave the building. ATUM proudly holds a Silver rating from EcoVadis, a global standard for business sustainability ratings. The facility is powered by solar panels, harnessing the abundant energy of the California sun and notably, every component in the supply chain is Category 4 (animal-free), aligning with ATUM's dedication to sustainability.
With its unparalleled capabilities and commitment to sustainability, ATUM continues to drive the future of biotechnology forward.
About ATUM:
ATUM is a leading biotechnology company based in California, dedicated to serving life science researchers for over two decades. We offer top-quality services, including Gene Design and Synthesis, Protein Engineering and Production, Leap-In Transposase®, Cell Line Development, and Master Cell Banking (MCB).
Our advanced machine learning platform and proprietary algorithms, combined with a fully integrated Laboratory Information Management System (LIMS), enable seamless transition from electronic sequence to MCB. ATUM is committed to innovation, providing bioengineered solutions that accelerate market readiness, supporting your journey from pre-clinical research through IND and beyond.
